| Document |
Document Title |
|
WO/2024/084362A1 |
The present invention relates to a stable crystalline form of Tafamidis having characteristic 2-theta peaks at 13.6±0.2, 20.4±0.2 and 27.5±0.2. The present invention provides Tafamidis having particle size (d90) less than 100 microns....
|
|
WO/2024/083210A1 |
Among other things, the present disclosure provides compounds, e.g., of formula I or salts thereof. In some embodiments, the present disclosure provides methods for modulating MRGPRX4 activity. In some embodiments, the present disclosure...
|
|
WO/2024/078372A1 |
Provided are a heterocyclic substituted phenol derivative, a preparation method therefor, and a use thereof. Specifically, provided are compounds of formulas (I-1), (II-1B), (III), and (IV), stereoisomers thereof, pharmaceutically accept...
|
|
WO/2024/079276A1 |
The present invention relates to a method for synthesising a photolytically degradable compound, the method comprising defining a biologically active compound which analogue is to be synthesised, wherein the biologically active compound ...
|
|
WO/2024/075825A1 |
The present invention addresses the problem of providing a novel compound that has an OX2R agonist activity. The present invention pertains to a cyclopentane compound represented by formula (I) or a pharmacologically acceptable salt th...
|
|
WO/2024/075051A1 |
Described herein are compounds of Formula I, wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD an...
|
|
WO/2024/071538A1 |
The present invention relates to a novel benzoxazole derivative comprising 4-amino-butanamide and an anti-inflammatory use thereof.
|
|
WO/2024/069378A1 |
The present invention provides novel compounds of Formula (I) or its pharmaceutically acceptable salts. The novel compounds reported in present invention are suitable for the treatment against infection caused by Gram-positive bacteria.
|
|
WO/2024/067783A1 |
Provided are a compound represented by formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and use of the compound as an androgen receptor (AR) inhibitor.
|
|
WO/2024/072930A1 |
D3R selective partial agonists and their use in treating substance use disorders alone or in combination with affective disorders are disclosed. These substance use disorders include psychostimulant use disorder (PSUD). Compounds include...
|
|
WO/2024/060739A1 |
The present application relates to an organic compound, an electronic element comprising same, and an electronic device. The structural formula of the organic compound of the present application is represented by formula 1; the organic c...
|
|
WO/2024/060668A1 |
The present application relates to the technical field of organic electroluminescent materials, and provides a nitrogen-containing compound, an organic electroluminescent device comprising same, and an electronic apparatus. The nitrogen-...
|
|
WO/2024/059659A1 |
Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, Y1, Y2, X1, X2, X3, Q1, and Ra are as defined elsewhere herein. Also provid...
|
|
WO/2024/059661A1 |
Provided herein are compounds of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R1, R2, R3, R4, Y1, Y2, X1, X2, L, and Q1 are as defined elsewhere herein. A...
|
|
WO/2024/054279A1 |
The present invention is directed to novel chemical compositions of matter, and in particular a novel MDMA class of compounds MDMA analogs having 1,3-benzothiazoles substituted at the 5 and 6-position with a MDMA basic or modified side c...
|
|
WO/2024/047227A1 |
The present invention relates to compounds of Formula (I) and (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical c...
|
|
WO/2024/039119A1 |
The present invention provides: a novel compound which can improve the luminous efficiency, stability, and service life of an element; an organic electric element using same; and an electronic device thereof.
|
|
WO/2024/035876A2 |
Disclosed herein are compositions and methods for treating glioblastoma.
|
|
WO/2024/033374A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2024/031997A1 |
The present invention relates to N-N-bis-oxazolidinone alkaloid compounds, a preparation method and a use in the medical field. The present invention provides two new N-N-bis-oxazolidinone alkaloid isomers isolated and purified from Loni...
|
|
WO/2024/030651A1 |
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, sp...
|
|
WO/2024/026359A1 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds that are inhibitors for thioredoxin glutathione reductase (TGR), which is key for ...
|
|
WO/2024/024965A1 |
The present invention addresses the problem of providing a method for producing an O-substituted serine derivative, which makes it possible to produce an O-substituted serine derivative in fewer steps. The present inventors have made ext...
|
|
WO/2024/019444A1 |
Provided is an organic compound contributing to improving the substantial light efficiency and field of view of an organic electroluminescent device. The organic electroluminescent device according to the present invention comprises: a f...
|
|
WO/2024/020350A1 |
The present disclosure provides, in part, compounds of formula (I): wherein the variables are as defined herein, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat physiological disorders, s...
|
|
WO/2024/019180A1 |
The present invention provides a method with which it is possible to produce tafamidis or a salt thereof with high yield. This production method for tafamidis or a salt thereof comprises a cyclization step for obtaining a compound repr...
|
|
WO/2024/011415A1 |
Disclosed in the present invention is a method for preparing an o-iodophenyl compound, wherein an iodobenzene compound and an amide compound as raw materials are reacted in the presence of sodium hydride or n-butyllithium and a solvent t...
|
|
WO/2023/280638A9 |
The application relates to vinyl thianthrenium compounds Vinyl- TT+X- of the Formula (I), a process for preparing the same and the use thereof for vinylating organic compounds.
|
|
WO/2024/010050A1 |
[Problem] The purpose of the present invention is to provide a compound that prevents internal elemental deterioration of an organic EL element, that, in order to significantly improve light-extraction efficiency, does not affect materia...
|
|
WO/2024/011155A1 |
Described herein are oxazole TRPML1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of TRPML1-mediated disorders or diseases.
|
|
WO/2024/008166A1 |
Provided in the present invention are an α,β-unsaturated amide compound, and a preparation method therefor, and a pharmaceutical composition and the use thereof. Specifically, provided in the present invention is a compound as represen...
|
|
WO/2024/005586A1 |
The present invention relates to a novel crystalline form of 5-((2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazo
l-4-yl)methoxy)phenyl)ethynyl)-2-cyclopropylbenzo[d]oxazole-
7-carboxylic acid or a salt thereof.
|
|
WO/2023/249007A1 |
The present invention provides a calpain inhibitor that has excellent calpain inhibitive capacity. The present invention provides a compound represented by general formula (I), or a salt thereof. (In formula (I), R1 represents a hydrogen...
|
|
WO/2023/249872A1 |
The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Also provided related pharmaceutical compositions and methods of treating narcolepsy or cataplexy in a subject in ...
|
|
WO/2023/236263A1 |
The present invention provides a benzoxazole derivative, a preparation method therefor, and an application thereof. The benzoxazole derivative provided by the present invention has a structure as represented by formula (I). Experimental ...
|
|
WO/2023/235384A1 |
Disclosed herein are new aromatic compounds, compositions that include one or more aromatic compounds, and methods of synthesizing the same. Also disclosed herein are methods of enhancing readthrough of genes containing premature termina...
|
|
WO/2023/224981A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2023/218203A1 |
The present invention relates to compounds that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical c...
|
|
WO/2023/209191A1 |
The invention concerns a novel class of Prolyl oligopeptidase binding ligands, a pharmaceutical composition comprising same, the use of said ligands as medicaments, particularly, but not exclusively to promote autophagy and/or treat a di...
|
|
WO/2023/210599A1 |
The present invention provides a compound represented by general formula[1] and having a DDR1 kinase inhibitory activity, a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable...
|
|
WO/2023/206874A1 |
A sacubitril intermediate, a preparation method therefor, and use thereof. A key intermediate N-Boc amino alcohol represented by formula (10) or formula (10-a) can be efficiently prepared. The intermediate can be used to prepare a neutra...
|
|
WO/2023/203503A1 |
The present invention relates to a process for the preparation of crystalline Form 4 of tafamidis from tafamidis meglumine salt.
|
|
WO/2023/200315A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2023/190976A1 |
Provided is a novel therapeutic agent that is useful for treating a chronic lung disease such as COPD or IPF. The present invention relates to a pharmaceutical composition for treating a chronic lung disease that contains a therapeutic...
|
|
WO/2023/182775A1 |
The present invention pertains to: a novel aromatic heterocyclic compound that can be used in an organic light-emitting diode; and an organic light-emitting diode including same.
|
|
WO/2023/177217A1 |
The present invention relates to: a novel aromatic heterocyclic compound to be used in an organic light-emitting diode; and the organic light-emitting diode comprising same.
|
|
WO/2023/171980A1 |
The present invention relates to a novel tafamidis preparation method having economic feasibility even while having an excellent synthesis yield. More specifically, the present invention relates to a novel method for synthesizing tafamid...
|
|
WO/2023/166303A1 |
The invention relates to compounds of formula (I): (I) and related aspects.
|
|
WO/2023/152182A1 |
Present invention relates to a compound according to formula (II): and all stereoisomers, racemic mixtures, tautomers, pharmaceutically acceptable salts, prodrugs, hydrates, solvates and polymorphs thereof, as well as pharmaceutical comp...
|
|
WO/2023/151897A1 |
The invention relates to compounds of general formula (I).
|
